Researcher Receives Howard Hughes Medical Institute Investigator Designation
Cincinnati Children’s researcher Jeffery D. Molkentin, PhD, has been named one of 56 new Howard Hughes Medical Institute (HHMI) investigators.
A researcher in the Division of Cardiovascular Molecular Biology at Cincinnati Children’s, Dr. Molkentin was among 1,070 scientists who applied for the appointment.
This designation will place Dr. Molkentin among the nation’s most promising scientists who are challenged to pursue bold and creative research.
Dr. Molkentin is the fourth HHMI investigator ever in Ohio and the first at Cincinnati Children’s.
In making its selections, HHMI sought outstanding scientists studying biomedical problems in a variety of disciplines.
“We look for scientists who have demonstrated originality and productivity in biomedical research and show exceptional potential for future contributions,” said Jack E. Dixon, PhD, vice president and chief scientific officer at HHMI. “This infusion of fresh scientific talent allows us to refresh our commitment to original and creative biomedical research.”
Dr. Molkentin’s research has advanced the understanding of molecular events behind heart disease and muscular dystrophy. His team studies the signaling mechanisms that control cell growth, differentiation and death.
